Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
-
+
P16 - Immunotherapy (Phase II/III Trials) - First-Line, Advanced NSCLC
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 7
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P16.04 - A Phase II Clinical Study Evaluating Camrelizumab Combined With Apatinib and Albumin Paclitaxel for Advanced Non-Small CellLung Cancer
00:00 - 00:00 | Presenter: Lin Wu
- Abstract
Loading...
-
+
P17 - Immunotherapy (Phase II/III Trials) - First-Line, Advanced, Squamous NSCLC
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 3
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P17.01 - KEYNOTE-407 China Extension Final Analysis: Pembrolizumab Plus Chemotherapy for the Treatment of Metastatic Squamous NSCLC
00:00 - 00:00 | Presenter: Ying Cheng
- Abstract
Loading...
-
+
P40 - Multimodality of Advanced Lung Cancer - Clinical Outcomes
- Type: Posters
- Track: Multimodality of Advanced Lung Cancer
- Presentations: 20
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P40.14 - Efficacy and Safety of Endostar Combined With Camrelizumab and Chemotherapy in Treatment of Advanced NSCLC: A Multi-Center Retrospective Study
00:00 - 00:00 | Presenter: Lin Wu
- Abstract
Loading...
-
+
P48 - Novel Therapeutics and Targeted Therapies - EGFR
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 17
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P48.01 - Anlotinib Plus Docetaxel vs Docetaxel for 2nd-Line Treatment of EGFR negative NSCLC (ALTER-L018): A Randomized Phase II Trial
00:00 - 00:00 | Presenter: Lin Wu
- Abstract
Loading...
-
+
MA01 - Multimodality Management of Advanced Lung Cancer
- Type: Mini Oral
- Track: Multimodality of Advanced Lung Cancer
- Presentations: 8
- Coordinates: 9/08/2021, 08:15 - 09:15, Program Auditorium
-
+
MA01.05 - Sintilimab, SBRT and GM-CSF for Advanced NSCLC: Safety Run-in Results of a Prospective, Multicenter, Phase II Trial
08:45 - 08:50 | Presenter: Jianjiao Ni
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA02 - RET and Novel Combinations of Osimertinib
- Type: Mini Oral
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 8
- Coordinates: 9/08/2021, 09:30 - 10:30, Program Auditorium
-
+
MA02.01 - Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial
09:30 - 09:35 | Presenter: Shun Lu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?
- Type: Mini Oral
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 9
- Coordinates: 9/13/2021, 17:30 - 18:30, Program Auditorium
-
+
MA13.08 - CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
18:10 - 18:15 | Presenter: Jie Wang
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
